ClinicalTrials.gg
CompletedNCT01332578Updated Jun 1, 2015Results posted

A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies

A Phase 4 interventional study of Paracetamol and Phenylephrine in Influenza and Common Cold, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-01.

Sponsored by GlaxoSmithKline · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Influenza, Human by GlaxoSmithKline — 3 open to participants now, 3 under way, 2 of them phase 3. Influenza, Human · GlaxoSmithKline.

Enrollment
152nd of 165
25 · median 324
Started
2011
with 15 others
Phase 4
12 of 187
none open now
Registered
123rd of 187
by date

Among the 187 studies in Influenza, Human by GlaxoSmithKline, this one is the 152nd largest by enrollment of the 165 interventional ones that give a count, is one of 16 that started in 2011, is one of 12 in phase 4, and was the 123rd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 187 studies in Influenza, Human by GlaxoSmithKline are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Influenza, Human by GlaxoSmithKline, or all of them as a file.
02

Study summary

The study is designed to investigate whether paracetamol from a hot remedy reaches the plasma faster than standard paracetamol tablets. The study will also assess the gastrointestinal transit of two oral cold and influenza ('flu') formulations using gamma scintigraphy. It is postulated that paracetamol in solution, such as from cold and 'flu' hot remedies, provides a greater early exposure compared to standard paracetamol tablets. In addition, the pharmacokinetic (PK) profile of paracetamol in the two formulations will be investigated.

03

Conditions studied

  • Influenza
  • Common Cold
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

  • Healthy male volunteers
  • between 18.0-29.9 kg/m\^2
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Test Product

    Paracetamol, phenylephrine and ascorbic acid to be administered in 150 milliliters (mL) of hot water.

    Drug: Paracetamol · Drug: Phenylephrine · Drug: Ascorbic Acid

  • Active comparator
    Paracetamol tablet

    Two paracetamol 500 mg tablets to be administered with 150 mL of hot water.

    Drug: Paracetamol

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Reach Plasma Paracetamol Concentration of 0.25 μg/mL (Microgram Per Milliliter)

    Time to reach plasma paracetamol concentration of 0.25 μg/mL was determined using plasma concentration time profiles.

    Time frame: Blood samples taken within 15-30 minutes prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose

Secondary outcomes

  1. Area Under the Concentration/Time Curve From 0 to 30 Minutes (Min) (AUC 0-30 Min)

    AUC (0-30 min) was determined from paracetamol plasma concentration time profiles using trapezoidal rule.

    Time frame: Blood samples taken within 15-30 min prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose

  2. AUC (0-60 Min)

    AUC (0-60 min) was determined from paracetamol plasma concentration time profiles using trapezoidal method.

    Time frame: Blood samples taken within 15-30 min prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose

  3. Maximum Plasma Concentration (Cmax)

    Cmax was determined using plasma paracetamol concentration time profile.

    Time frame: Blood samples taken within 15-30 min prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose

  4. Time to Maximum Plasma Concentration (Tmax)

    Time after administration when the maximum plasma concentration was reached.

    Time frame: Blood samples taken within 15-30 min prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose

  5. Time to Onset of Gastric Emptying

    The individual anterior and posterior images were assessed using Gamma Scintigraphy images and WebLink Image Analysis program to determine the time to onset of gastric emptying of hot drink remedy and standard paracetamol tablets.

    Time frame: Baseline to 10 hours

  6. Time to Completion of Gastric Emptying

    Time to completion of gastric emptying of hot drink remedy and standard paracetamol tablets was assessed using Gamma Scintigraphy images and WebLink image analysis program. Completion of gastric emptying was confirmed by two consecutive images with negligible gastric activity.

    Time frame: Baseline to 10 hours

  7. Time to Onset and Completion of Disintegration of Reference Tablets

    Qualitative onset and completion of tablet disintegration was determined using Gamma scintigraphy images and WebLink image analysis program.

    Time frame: Baseline to 10 hours post dose

07

Results

Posted Jun 1, 2015

Participant flow

Participants were recruited at one clinical study site in Glasgow.

Period I
Participant flow — Period I
MilestoneHot Drink Remedy First, Then Standard Paracetamol TabletsStandard Paracetamol Tablets First, Then Hot Drink Remedy
Started1213
Completed1213
Not completed00
Washout Period
Participant flow — Washout Period
MilestoneHot Drink Remedy First, Then Standard Paracetamol TabletsStandard Paracetamol Tablets First, Then Hot Drink Remedy
Started1213
Completed1213
Not completed00
Period II
Participant flow — Period II
MilestoneHot Drink Remedy First, Then Standard Paracetamol TabletsStandard Paracetamol Tablets First, Then Hot Drink Remedy
Started1213
Completed1213
Not completed00

Outcome measures

PrimaryTime to Reach Plasma Paracetamol Concentration of 0.25 μg/mL (Microgram Per Milliliter)

Time to reach plasma paracetamol concentration of 0.25 μg/mL was determined using plasma concentration time profiles.

Time frame:
Blood samples taken within 15-30 minutes prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose
Reported as:
Median · minutes
Time to Reach Plasma Paracetamol Concentration of 0.25 μg/mL (Microgram Per Milliliter)
minutesHot Drink RemedyStandard Paracetamol Tablets
Time to Reach Plasma Paracetamol Concentration of 0.25 μg/mL (Microgram Per Milliliter)4.59 (3.4 to 11.1)23.14 (6.0 to 46.6)
Statistical analysis
  • Hot Drink Remedy vs Standard Paracetamol Tablets · Wilcoxon (Mann-Whitney) · p = 0.0004 · Median difference (final values): -20.92 · 95% CI -27.31 to -15.81Hodges-Lehmann estimate of median difference was determined.
SecondaryArea Under the Concentration/Time Curve From 0 to 30 Minutes (Min) (AUC 0-30 Min)

AUC (0-30 min) was determined from paracetamol plasma concentration time profiles using trapezoidal rule.

Time frame:
Blood samples taken within 15-30 min prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose
Reported as:
Mean · nanograms (ng)*hours (h)/mL
Area Under the Concentration/Time Curve From 0 to 30 Minutes (Min) (AUC 0-30 Min)
nanograms (ng)*hours (h)/mLHot Drink RemedyStandard Paracetamol Tablets
Area Under the Concentration/Time Curve From 0 to 30 Minutes (Min) (AUC 0-30 Min)1535.80 ± 873.300387.28 ± 363.139
SecondaryAUC (0-60 Min)

AUC (0-60 min) was determined from paracetamol plasma concentration time profiles using trapezoidal method.

Time frame:
Blood samples taken within 15-30 min prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose
Reported as:
Mean · ng*h/mL
AUC (0-60 Min)
ng*h/mLHot Drink RemedyStandard Paracetamol Tablets
AUC (0-60 Min)5007.11 ± 1890.1351874.22 ± 1555.539
SecondaryMaximum Plasma Concentration (Cmax)

Cmax was determined using plasma paracetamol concentration time profile.

Time frame:
Blood samples taken within 15-30 min prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax)
ng/mLHot Drink RemedyStandard Paracetamol Tablets
Maximum Plasma Concentration (Cmax)8309.58 ± 2109.1969225.20 ± 1681.200
SecondaryTime to Maximum Plasma Concentration (Tmax)

Time after administration when the maximum plasma concentration was reached.

Time frame:
Blood samples taken within 15-30 min prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax)
hoursHot Drink RemedyStandard Paracetamol Tablets
Time to Maximum Plasma Concentration (Tmax)1.50 (0.2 to 2.0)1.99 (0.7 to 3.0)
SecondaryTime to Onset of Gastric Emptying

The individual anterior and posterior images were assessed using Gamma Scintigraphy images and WebLink Image Analysis program to determine the time to onset of gastric emptying of hot drink remedy and standard paracetamol tablets.

Time frame:
Baseline to 10 hours
Reported as:
Least squares mean · minutes
Time to Onset of Gastric Emptying
minutesHot Drink RemedyStandard Paracetamol Tablets
Time to Onset of Gastric Emptying7.86 ± 3.90954.23 ± 3.596
SecondaryTime to Completion of Gastric Emptying

Time to completion of gastric emptying of hot drink remedy and standard paracetamol tablets was assessed using Gamma Scintigraphy images and WebLink image analysis program. Completion of gastric emptying was confirmed by two consecutive images with negligible gastric activity.

Time frame:
Baseline to 10 hours
Reported as:
Least squares mean · minutes
Time to Completion of Gastric Emptying
minutesHot Drink RemedyStandard Paracetamol Tablets
Time to Completion of Gastric Emptying202.59 ± 16.811168.38 ± 15.463
SecondaryTime to Onset and Completion of Disintegration of Reference Tablets

Qualitative onset and completion of tablet disintegration was determined using Gamma scintigraphy images and WebLink image analysis program.

Time frame:
Baseline to 10 hours post dose
Reported as:
Mean · minutes
Time to Onset and Completion of Disintegration of Reference Tablets
minutesStandard Paracetamol Tablets
Onset Time of Disintegration42.50 ± 18.028
Completion Time of Disintegration62.88 ± 24.788

Adverse events

Collected over Adverse events were collected from the start of the treatment, and until 5 days following administration of the last dose of investigational product.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hot Drink Remedy—0/25 (0%)3/25 (12%)
Standard Paracetamol Tablets—0/25 (0%)3/25 (12%)
Most frequent other events
Most frequent other events
EventHot Drink RemedyStandard Paracetamol Tablets
HematuriaRenal and urinary disorders2/250/25
Alanine Aminotransferase IncreasedInvestigations0/251/25
Blood Bilirubin IncreasedInvestigations0/251/25
BlepharospasmEye disorders1/250/25
HeadacheNervous system disorders0/251/25

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Randomized Participants
Mean30.5 ± 11.23
Sex: Female, Male
Sex: Female, Male(Participants)All Randomized Participants
Female0
Male25
08

Study locations

1 site
  • BIO-IMAGES Research Ltd.
    Glasgow, Scotland G63 0BX, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2011
First posted
Apr 11, 2011
Start
May 2011
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Jun 1, 2015
Last update
Jun 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01332578
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 11, 2011
Start date
May 2011
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Jun 1, 2015
Last update
Jun 1, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Phenylephrine · Ascorbic Acid

Start the discussion